Detalhe da pesquisa
1.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Ann Surg Oncol
; 30(13): 8353-8361, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658272
2.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Ann Surg Oncol
; 2022 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378634
3.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Oncologist
; 26(3): e382-e393, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098195
4.
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.
Ann Surg Oncol
; 23(10): 3317-23, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27384749
5.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Surg Oncol
; 45: 101885, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36436423
6.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
JCO Precis Oncol
; 6: e2200197, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108259
7.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
JCO Precis Oncol
; 6: e2100463, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476550
8.
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.
NPJ Breast Cancer
; 5: 15, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31016233
9.
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
Clin Cancer Res
; 25(17): 5388-5397, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142502